This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence.
The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system. Can pharma tariffs “Make America Manufacture Again”?
This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Can pharma tariffs “Make America Manufacture Again”? Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments.
July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain. Credit: design_cam/Shutterstock.com. Give your business an edge with our leading industry insights.
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Can pharma tariffs “Make America Manufacture Again”? Credit: luchschenF /Shutterstock.
Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.
It employs a function-first screening workflow to reveal rare and effective immune targets, thereby fast-tracking the next-generation prophylactics and treatments development. Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.
fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.
The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Can pharma tariffs “Make America Manufacture Again”? Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding.
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Give your business an edge with our leading industry insights.
The technology stabilises viral proteins in their native shape, which may lead to more effective immune responses. Find out more Sanofi’s acquisition adds an early-stage combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as the Molecular Clamp technology.
June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The treatments can be accessed through facilities such as Royal Prince Alfred Hospital, Westmead Hospital and the Sydney Children’s Hospitals Network. Can pharma tariffs “Make America Manufacture Again”? Credit: Bohbeh creations/Shutterstock.
It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity. Give your business an edge with our leading industry insights.
A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made.
CD4+T-cells and lymphocytes are both crucial elements of the immune system. Can pharma tariffs “Make America Manufacture Again”? Low levels of either increase the likelihood of infections and other health problems. HIV itself can reduce CD4 count – a value lower than 200 indicates acquired immunodeficiency syndrome (AIDS).
A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
Its design minimises interaction with Fc-gamma (Fcγ) receptors on macrophages, enhancing the ability of the body’s immune cells to recognise and combat tumours. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Can pharma tariffs “Make America Manufacture Again”? Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”
Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Brii Bio chairman and CEO Dr Zhi Hong stated: “The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. Find out more Sign up for our daily news round-up!
LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.
This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Can pharma tariffs “Make America Manufacture Again”?
The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.
By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Can pharma tariffs “Make America Manufacture Again”?
In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety. Can pharma tariffs “Make America Manufacture Again”?
RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. More recently, he blamed, without evidence, hospital error as the cause of recent paediatric deaths in children with measles, rather than the lack of immunisation against the disease.
A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Can pharma tariffs “Make America Manufacture Again”? Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.
The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus remdesivir compared to remdesivir alone in hospitalized adults with COVID-19. Preliminary data from prior small studies had suggested a potential benefit of interferon beta-1a, a natural antiviral component of the immune system, for COVID-19 patients.
If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. About the author.
That’s according to Dr Gareth Parkes – a full-time gastroenterologist who co-founded Ampersand Health, which develops digital therapeutics for inflammatory bowel disease (IBD) and other immune mediated inflammatory diseases (IMIDs). Every single hospital has a different process and a different set of forms to fill in.”.
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. This alone causes expense for cash-strapped hospitals and puts pressure on nursing and medical staff while they manage the side effects.
Amongst the new members on the CDC’s Advisory Committee for Immunization Practices (ACIP) are well-known vaccine sceptics and individuals who were critical of both the Covid-19 vaccines and related countermeasures such as lockdowns. Can pharma tariffs “Make America Manufacture Again”?
Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. and Banco Bilbao Vizcaya Argentaria S.A " LinkedIn Total experience: 29 yrs. LinkedIn Total experience: 31 yrs.
There is also the potential for the technology to be used to allow other industries such as hospitality and sport to restart, by ensuring those attending mass gatherings are free of the virus. But could digital immunity passports be the answer? Our focus should be on getting people vaccinated. About the author.
The medical groups also pointed to sweeping changes made on the CDC’s Advisory Committee for Immunization Practices (ACIP), the committee responsible for reviewing vaccine data and issuing official government recommendations on immunisations. There have been three confirmed deaths from the disease, all in unvaccinated children.
T-Mobile went into partnership with Verizon, AT&T, and iHeartMedia to give 40,000 phone chargers to hospitals, putting frightened, isolated patients back in touch with loved ones. Brands are contributing in myriad different, relevant and engaging ways. Verizon also donated $2.5
The SCOPE trial of SCIB1 and Scancells next-generation candidate iSCIB1+ show "excellent results encompassing efficacy, durability, immune responses and safety" when added to standard checkpoint inhibitor therapy for advanced melanoma untreatable with surgery, according to the company.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content